Investment firm Oberland Capital said today that it has closed its second royalty and credit opportunities fund, Oberland Capital Healthcare II LP (Fund II), at its hard cap of $800 million in capital commitments. The fund will target investments between $20 million and $150 million with a focus on commercial stage or near-commercial stage biopharmaceutical, […]